The gap between scientific evidence and clinical practice: 5‐aminosalicylates are frequently used for the treatment of Crohn's disease

201450 citationsJournal Articlebronze Open Access

Authors

Alain Schoepfer · University Hospital of Lausanne

M. Bortolotti · Institute of Social and Preventive Medicine

Valérie Pittet · Institute of Social and Preventive Medicine

Christian Mottet · University Hospital of Lausanne

J. J. Gonvers · University Hospital of Lausanne

Oliver Reich · Helsana Group (Switzerland)

Nicolas Fournier

Abstract

5-Aminosalicylates were frequently prescribed in patients with Crohn's disease in the Swiss IBD cohort. This observation stands in contrast to the scientific evidence demonstrating a very limited role of 5-ASA compounds in the treatment of Crohn's disease.

Topics & Keywords

Inflammatory Bowel Disease Eosinophilic Esophagitis Microscopic Colitis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Alimentary Pharmacology & Therapeutics

Volume 40, Issue 8, pp. 930-937

DOI: 10.1111/apt.12929

Field-Weighted Citation Impact: 2.80